Abstract：Objective To observe the efficacy of regular or intermittent inhalation of salmeterol/fluticasone propionate (SM/FP) in the treatment of bronchial asthma and its effects on growth and development in children. Methods A total of 112 children diagnosed with bronchial asthma between September 2012 and October 2013 were assigned to standardized treatment (standard group, n=56) and non-standardized treatment (intermittent group, n=56). Comparisons of clinical symptom scores and main pulmonary function indicators between the two groups were carried out before treatment and at 6 and 12 months after treatment. The growth velocity and changes in body mass index (BMI) were observed in the two groups. Results At 6 and 12 months after the treatment, the standard group had significantly reduced clinical symptom scores and significantly increased pulmonary function indicators (percentage of predicted peak expiratory flow, PEF%; percentage of forced expiratory volume in 1 second, FEV1%) (P<0.05); the intermittent group had significantly reduced clinical symptom scores and significantly increased FEV1% (P<0.05), but PEF% was significantly increased only at 6 months after treatment (P<0.05). At 12 months after treatment, the standard group had significantly lower clinical symptom scores and significantly higher PEF% and FEV1% when compared with the intermittent group (P<0.05). The growth velocity and BMI showed no significant differences between the two groups at 6 and 12 months after treatment (P>0.05). Conclusions Compared with intermittent inhalation, long-term regular inhalation of SM/FP performs better in controlling clinical symptoms and enhancing pulmonary function in children with asthma. Inhalation of SM/FP for one year reveals no apparent effect on the growth and development of these children.
LI Lin-Wei,HUANG Ying,LUO Rong et al. Efficacy of regular or intermittent inhalation of corticosteroids in treatment of asthma and its effects on growth and development in children[J]. CJCP, 2015, 17(3): 237-240.
Baraniuk JN, Ali M, Brody D, et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa[J]. Am J Respir Crit Care Med, 1997, 155(2): 704-710.
[6]
Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta 2-agonists and corticosteroids[J]. Eur Respir J, 2002, 19(1): 182-191.
Barnes NC, Jacques L, Goldfrad C, et al. Initiation of maintenance treatment with salmeterol/fluticasone propionate 50/100 microg bd versus fluticasone propionate 100 microg bd alone in patients with persistent asthma: integrated analysis of four randomized trials[J]. Respir Med, 2007, 101(11): 2358-2365.
[9]
Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma[J]. N Engl J Med, 2006, 354(19): 1985-1997.
[10]
Kelly HW, Sternberg AL, Lescher R, et al. Effect of inhaled glucocorticoids in childhood on adult height[J]. N Engl J Med, 2012, 367(10): 904-912.
[11]
Kostic G, Ilic N, Petrovic M, et al. Body mass index in asthmatic children before and after one year inhaled glucocorticosteroids therapy BMI[J]. Med Pregl, 2010, 63(5-6): 409-413.
